• Evolution of RBD in PD

  NCT03047408

  Unknown statusInterventionalNot ApplicableUpdated Feb 9, 2017
• Gait and REM Sleep Behavior Disorder

  NCT02554331

  TerminatedInterventionalNot ApplicableUpdated Dec 23, 2021
• Validity and Reliability of the French Translation of the Richards-Campbell Questionnaire

  NCT06945874

  CompletedObservationalUpdated Jun 17, 2026
• Neuroplasticity in RBD

  NCT05471960

  RecruitingInterventionalNot ApplicableUpdated Jun 10, 2026
• Microstructural and Sodium 7 Tesla Brain MRI in Idiopathic REM Sleep Behaviour Disorder

  NCT05976971

  CompletedInterventionalNot ApplicableUpdated Jan 21, 2026
• Unmet Needs Among Patients With Isolated REM Sleep Behavior Disorder (iRBD) and Their Significant Others

  NCT07498452

  RecruitingObservationalUpdated Mar 27, 2026

ClinicalTrials.gov ID

NCT04071899

Lead Sponsor

University Hospital, Clermont-FerrandOTHER

Overall Status

Unknown status

Study Type

Observational

Enrollment

80Estimated

Last Update Posted

Aug 28, 2019Actual

Start Date

May 24, 2019Actual

Primary Completion Date

Jun 24, 2020Estimated

Completion Date

Sep 24, 2020Estimated

Official Title

French Validation of a Severity Scale in REM Sleep Behavior Disorder

Brief Summary

REM (Rapid Eye Movements) Sleep Behavior Disorder (RBD) is a parasomnia characterized by episodes of elaborate or violent motor activity during dreams, which can lead to injury and sleep disruption in patient and / or his/her spouse. This is due to the loss of the normal muscle atonia during REM Sleep. RBD is often associated to neurodegenerative diseases, and may even precede them for several years as an early marker. Currently, there is no scale or tool for assessing the severity of RBD. Nevertheless, it is crucial to have a tool of severity when one wants to study the natural evolution of this disorder, as well as the possible effect of a drug in the context of a clinical trial. A Severity Scale of RBD has recently been proposed within the International RBD Study Group and an international validation study in several languages is being considered.

The main objective of this study is to validate a new scale of severity of the REM sleep behavior disorder (RBD Severity Scale or RBDSS) and to characterize its metrological properties, in particular its concurrent validity, internal consistency and reproducibility

Detailed Description

Research involving the human person, non-interventional, category 3

80 patients with RBD of any etiology (eg Idiopathic RBD, RBD associated with Parkinson's Disease, Multiple System Atrophy, Narcolepsy etc.) and their bedpartners (if available) will be include in 5 French centers (Clermont-Ferrand, Paris, Nantes, Montpellier et Lyon) Patients, and their bedpartners (if available), will be seen 2 times at 1 week intervals.

For the patients Visit 1 (Day 0): duration : 60 minutes

• Information to patient and collection of non-opposition
• Collection of socio-demographic data: age, sex, level of education
• Clinical data collection: duration of RBD, duration and severity of the concomitant disease:, medical and surgical history
• Assessment of cognitive functions: Mini Mental State Examination
• Verification of inclusion / exclusion criteria
• Ongoing treatments and calculation of Levodopa Equivalent Daily Dose (LEDD) for PD patients.
• RBD severity scale for Patient (RBDSS-PT) + Global Clinical Impression-Severity Scale

Visit 2 (J7) : duration : 20 minutes

• Ongoing treatments
• RBDSS PT + Global Clinical Impression-Severity Scale (CGI-S-PT)
• Patient will be given a Weekly Severity Agenda for 4 weeks plus a copy of the RBSSS-PT + Global Clinical Impression-Severity Scale

At home, patients will fill :

D8 à D36 :

• Weekly Severity Agenda (wRBDQ) for 4 weeks

D36 :

• RBDSS-PT + Clinical Global Impression-Severity These documents will be mailed back in a pre-payed envelop. For the Bed Partners Visit 1 (D0- baseline): duration: 30 minutes
• Information of and collection of non opposition
• Collection of socio-demographic data: age, sex, level of education
• Assessment of cognitive functions: Mini Mental State Examination
• Verification of inclusion / exclusion criteria
• Ongoing Treatments
• RBD severity scale of the bed partner (RBDSS BP)+ Global Clinical Impression-Severity Scale

Visit 2 (D7- retest) : duration : 20 minutes

• Ongoing treatments
• RBDSS-BP + Clinical Overall Impression Severity Scale
• Patient will be given a Weekly Joint Severity Agenda to be completed together with the patient, (wRBDQ) for 4 weeks, plus a copy of the RBDSS-BP + CGI-S-BP

At home: bedpartners will fill:

D8 à D36 :

• Weekly Severity Agenda for 4 weeks, in common with patient

D36 :

• RBDSS-BP + Impression Global Clinique-Severity scale These documents will be mailed back in a pre-payed envelop.

• REM Sleep Behavior Disorder

• Scale vaidation

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion Criteria:

• RBD patients:

  • Men or women aged 30 to 80
  • Patients with idiopathic and secondary RBD (including RBD associated with Parkinson's disease, Narcolepsy, Multiple System Atrophy or other neurological diseases) diagnosed according to the latest international criteria Classification of Sleep Disorders (ICSD-3 ).
  • Cooperation and understanding to strictly comply with the conditions laid down in the protocol
  • Affiliated to a social security system
  • bedpartners
  • Men or women aged 30 to 80
  • Subjects sharing the same bed as the patient for ≥70% of the time (e.g. at least 5 nights / week, or 20 nights / month)
  • -Cooperation and understanding to strictly comply with the conditions described in the protocol
  • Affiliated to a social security system

Exclusion Criteria:

-- RBD patients:

• Clinically defined dementia according to the criteria of DSM-V2 (Major Neurocognitive Disorder)
• Untreated Obstructive Sleep Apnea Syndrome (OSAS) (with IAH> 15 / h at vPSG)
• Patients under tutorship or curatorship or safeguard of justice
• No change in treatment should have occurred during the 4 weeks prior to inclusion in the study and no change in treatment should be expected a priori within one week of inclusion
• Bedpartners
• Clinically defined dementia according to the criteria of DSM-V2 (Major Neurocognitive Disorder)
• Patients under tutorship or curatorship or safeguard of justice

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

University Hospital, Clermont-FerrandOTHER

Collaborators

Société Française de Recherche et Médecine du SommeilUNKNOWN

isabelle.arnulf@aphp.fr